These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21525185)

  • 1. Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.
    Jachimowicz RD; Fracasso G; Yazaki PJ; Power BE; Borchmann P; Engert A; Hansen HP; Reiners KS; Marie M; von Strandmann EP; Rothe A
    Mol Cancer Ther; 2011 Jun; 10(6):1036-45. PubMed ID: 21525185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.
    Rothe A; Jachimowicz RD; Borchmann S; Madlener M; Keßler J; Reiners KS; Sauer M; Hansen HP; Ullrich RT; Chatterjee S; Borchmann P; Yazaki P; Koslowsky TC; Engert A; Heukamp LC; Hallek M; von Strandmann EP
    Int J Cancer; 2014 Jun; 134(12):2829-40. PubMed ID: 24242212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo.
    von Strandmann EP; Hansen HP; Reiners KS; Schnell R; Borchmann P; Merkert S; Simhadri VR; Draube A; Reiser M; Purr I; Hallek M; Engert A
    Blood; 2006 Mar; 107(5):1955-62. PubMed ID: 16210338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NKG2D Immunoligand rG7S-MICA Enhances NK Cell-mediated Immunosurveillance in Colorectal Carcinoma.
    Wang T; Sun F; Wang Y; Jiang J; Pan M; Yuan M; Zhang H; Du X; Hezam K; Song K; Wang M; Zhang J
    J Immunother; 2018 Apr; 41(3):109-117. PubMed ID: 29528990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
    Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
    Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
    Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
    Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.
    Peipp M; Wesch D; Oberg HH; Lutz S; Muskulus A; van de Winkel JGJ; Parren PWHI; Burger R; Humpe A; Kabelitz D; Gramatzki M; Kellner C
    Scand J Immunol; 2017 Oct; 86(4):196-206. PubMed ID: 28708284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Variability of Human Cytomegalovirus Clinical Isolates Correlates With Altered Expression of Natural Killer Cell-Activating Ligands and IFN-γ.
    Galitska G; Coscia A; Forni D; Steinbrueck L; De Meo S; Biolatti M; De Andrea M; Cagliani R; Leone A; Bertino E; Schulz T; Santoni A; Landolfo S; Sironi M; Cerboni C; Dell'Oste V
    Front Immunol; 2021; 12():532484. PubMed ID: 33897679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
    Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
    Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells.
    Fernández-Messina L; Ashiru O; Agüera-González S; Reyburn HT; Valés-Gómez M
    J Cell Sci; 2011 Feb; 124(Pt 3):321-7. PubMed ID: 21224393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
    Zhang T; Sentman CL
    Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.
    Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA
    Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
    Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
    Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
    J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell.
    Bae DS; Hwang YK; Lee JK
    Cell Immunol; 2012; 276(1-2):122-7. PubMed ID: 22613008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
    Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
    Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Natural Killer cell expression of ULBP2 is associated with a mature functional phenotype.
    Brennan K; McSharry BP; Keating S; Petrasca A; O'Reilly VP; Keane J; Doherty DG; Gardiner CM
    Hum Immunol; 2016 Oct; 77(10):876-885. PubMed ID: 27349945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.